CAR-T Cell Therapy Market to Surpass USD 188.84 Billion by 2034 at 36.8% during 2025 to 2034 – Report by Polaris Market Research
19 déc. 2024 04h47 HE
|
Polaris Market Research & Consulting LLP
New York, USA, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Market Overview The market for CAR-T cell therapy is poised to exhibit a robust CAGR of 36.8% during 2025–2034. The CAR-T cell therapy market size...
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
17 déc. 2024 08h00 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
10 déc. 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
09 déc. 2024 21h00 HE
|
Lyell Immunopharma, Inc
Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2 prior...
Monthly information on share capital and company voting rights
04 déc. 2024 16h30 HE
|
Cellectis Inc.
PARIS, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
CAR T-cell Therapy Strategic Business Research Report 2024: Global Market to Reach $10.8 Billion by 2030 - Expanding Clinical Applications Beyond Blood Cancers Expands Opportunities
02 déc. 2024 06h31 HE
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for CAR T-cell...
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
12 nov. 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and
Provides Business Update
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
08 nov. 2024 16h23 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia
ARTIDIS announces publication demonstrating the nanomechanical signature of response to low-dose radiotherapy followed by CAR T cell therapy in solid tumors.
08 nov. 2024 08h00 HE
|
Artidis AG
BASEL, Nov. 8, 2024 — ARTIDIS, a clinical-stage health technology company developing the first clinically integrated nanomechanical platform for tissue analytics, today announced a peer-reviewed...
CARGO Therapeutics to Participate in Upcoming Investor Conferences
05 nov. 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences